| 000 | 01105nam a2200241 a 4500 | ||
|---|---|---|---|
| 001 | 000538257 | ||
| 003 | AM-YeNLA | ||
| 005 | 20190426132718.0 | ||
| 008 | 070523s1996 sq |||||r|||||000|0|eng|d | ||
| 020 | _a92-832-1266-5 | ||
| 041 | 0 | _aeng | |
| 245 | 0 | 0 |
_aSome Pharmaceutical Drugs : _b[views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 13-20 Febbbruary 1996] / _cInternational Agency for Research on Cancer, World Health Organization. |
| 260 |
_aGeneva : _bWorld Health Organization, _c1996. |
||
| 300 |
_a514 p. : _bil. ; _c22 cm. |
||
| 440 | 0 |
_aIARC Monographs on the Evaluation of Carcinogenic Risks to Humans _nvol. 66 _x0250-9555 |
|
| 504 | _aIncludes bibliographical references and index | ||
| 650 | 1 | 4 |
_aCarcinogens _vcongresses |
| 650 | 1 | 4 |
_aDrugs _vcongresses |
| 650 | 1 | 4 |
_aNeoplasms _vchemically induced _xcongresses |
| 710 | 2 | _aInternational Agency for Research on Cancer | |
| 710 | 2 | _aWorld Health Organization | |
| 711 | 2 |
_aIARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Meeting _c(Lyon, France) |
|
| 999 |
_c466224 _d466224 |
||